Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion type Assertion NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_head.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion description "[The type I EGF receptor (EGFR or ErbB1) and insulin-like growth factor-binding protein-3 (IGFBP-3) are highly expressed in triple-negative breast cancer (TNBC), a particularly aggressive disease that cannot be treated with conventional therapies targeting the estrogen or progesterone receptors (ER and PR), or HER2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion evidence source_evidence_literature NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion SIO_000772 24337110 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion wasDerivedFrom befree-20150227 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.
- NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_assertion wasGeneratedBy ECO_0000203 NP380577.RAVWOHizFzQHy0kUnKgKXl35WixM4fuNlZyGEIEQpJ-FQ130_provenance.